Basel Medical Group Ltd (NASDAQ:BMGL – Get Free Report) saw a significant drop in short interest in September. As of September 30th, there was short interest totaling 11,310 shares, a drop of 92.9% from the September 15th total of 159,585 shares. Based on an average daily trading volume, of 57,193 shares, the short-interest ratio is presently 0.2 days. Currently, 0.7% of the company’s stock are short sold.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings upgraded Basel Medical Group from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, September 25th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.
View Our Latest Analysis on Basel Medical Group
Basel Medical Group Stock Up 4.2%
Basel Medical Group Company Profile
Basel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.
See Also
- Five stocks we like better than Basel Medical Group
- 3 Stocks Chopped in Half: Why These Drops May Be Structural, Not a Dip
- Home Depot and Lowe’s Hit 52-Week Lows—But Analysts Aren’t Giving Up
- Utilities Are Bouncing Back—These 2 Giants Could Signal the Next Big Sector Rally
- Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes Next
Receive News & Ratings for Basel Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basel Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.
